NASDAQ:ADAP Adaptimmune Therapeutics (ADAP) Stock Price, News & Analysis $0.28 -0.01 (-4.28%) Closing price 04:00 PM EasternExtended Trading$0.28 +0.00 (+1.09%) As of 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Adaptimmune Therapeutics Stock (NASDAQ:ADAP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ADAP alerts:Sign Up Key Stats Today's Range$0.27▼$0.3050-Day Range$0.20▼$0.4652-Week Range$0.20▼$1.48Volume328,423 shsAverage Volume1.83 million shsMarket Capitalization$70.74 millionP/E RatioN/ADividend YieldN/APrice Target$1.52Consensus RatingHold Company OverviewAdaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.Read More… Adaptimmune Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreADAP MarketRank™: Adaptimmune Therapeutics scored higher than 55% of companies evaluated by MarketBeat, and ranked 462nd out of 915 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingAdaptimmune Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 4 buy ratings, 2 hold ratings, and 1 sell rating.Amount of Analyst CoverageAdaptimmune Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Adaptimmune Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Adaptimmune Therapeutics are expected to decrease in the coming year, from ($0.14) to ($0.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adaptimmune Therapeutics is -1.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adaptimmune Therapeutics is -1.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdaptimmune Therapeutics has a P/B Ratio of 1.62. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.73% of the outstanding shares of Adaptimmune Therapeutics have been sold short.Short Interest Ratio / Days to CoverAdaptimmune Therapeutics has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Adaptimmune Therapeutics has recently decreased by 3.05%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAdaptimmune Therapeutics does not currently pay a dividend.Dividend GrowthAdaptimmune Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.73% of the outstanding shares of Adaptimmune Therapeutics have been sold short.Short Interest Ratio / Days to CoverAdaptimmune Therapeutics has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Adaptimmune Therapeutics has recently decreased by 3.05%, indicating that investor sentiment is improving. News and Social Media2.3 / 5News Sentiment0.11 News SentimentAdaptimmune Therapeutics has a news sentiment score of 0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Adaptimmune Therapeutics this week, compared to 2 articles on an average week.Search Interest8 people have searched for ADAP on MarketBeat in the last 30 days. This is an increase of 700% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Adaptimmune Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Adaptimmune Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders12.74% of the stock of Adaptimmune Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 31.37% of the stock of Adaptimmune Therapeutics is held by institutions.Read more about Adaptimmune Therapeutics' insider trading history. Receive ADAP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adaptimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ADAP Stock News HeadlinesHC Wainwright Brokers Boost Earnings Estimates for ADAPMay 18 at 2:11 AM | americanbankingnews.comStockNews.com Initiates Coverage on Adaptimmune Therapeutics (NASDAQ:ADAP)May 18 at 1:23 AM | americanbankingnews.comThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?May 21, 2025 | Timothy Sykes (Ad)Leerink Partnrs Has Bullish Estimate for ADAP Q2 EarningsMay 17, 2025 | americanbankingnews.comWells Fargo & Company Cuts Adaptimmune Therapeutics (NASDAQ:ADAP) Price Target to $1.00May 17, 2025 | americanbankingnews.comBarclays Cuts Adaptimmune Therapeutics (NASDAQ:ADAP) Price Target to $0.46May 17, 2025 | americanbankingnews.comAdaptimmune Therapeutics plc (NASDAQ:ADAP) Q1 2025 Earnings Call TranscriptMay 14, 2025 | insidermonkey.comAdaptimmune Therapeutics PLC (ADAP) Q1 2025 Earnings Call Highlights: Strong Tecelra Launch ...May 14, 2025 | finance.yahoo.comSee More Headlines ADAP Stock Analysis - Frequently Asked Questions How have ADAP shares performed this year? Adaptimmune Therapeutics' stock was trading at $0.5387 on January 1st, 2025. Since then, ADAP stock has decreased by 49.0% and is now trading at $0.2750. View the best growth stocks for 2025 here. How were Adaptimmune Therapeutics' earnings last quarter? Adaptimmune Therapeutics plc (NASDAQ:ADAP) announced its earnings results on Tuesday, May, 13th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.18). The biotechnology company had revenue of $7.29 million for the quarter, compared to analysts' expectations of $6.55 million. Adaptimmune Therapeutics had a negative net margin of 25.43% and a negative trailing twelve-month return on equity of 74.15%. Read the conference call transcript. When did Adaptimmune Therapeutics IPO? Adaptimmune Therapeutics (ADAP) raised $150 million in an initial public offering (IPO) on Wednesday, May 6th 2015. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners served as the underwriters for the IPO and Guggenheim Securities was co-manager. Who are Adaptimmune Therapeutics' major shareholders? Adaptimmune Therapeutics' top institutional investors include Long Focus Capital Management LLC (9.24%), Two Seas Capital LP (7.98%), MPM Asset Management LLC (2.07%) and MPM Bioimpact LLC (1.90%). Insiders that own company stock include Garry E Menzel, Cintia Piccina, Adrian Rawcliffe, William C Bertrand Jr, Elliot Norry and John Lunger. View institutional ownership trends. How do I buy shares of Adaptimmune Therapeutics? Shares of ADAP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Adaptimmune Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Adaptimmune Therapeutics investors own include Voyager Therapeutics (VYGR), Waste Connections (WCN), DiamondRock Hospitality (DRH), American Water Works (AWK), The RMR Group (RMR), AUO (AUOTY) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings5/13/2025Today5/21/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ADAP CIK1621227 Webwww.adaptimmune.com Phone441235430000Fax44-12-3543-0001Employees490Year FoundedN/APrice Target and Rating Average Stock Price Target$1.52 High Stock Price Target$3.00 Low Stock Price Target$0.46 Potential Upside/Downside+429.0%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-113,870,000.00 Net Margins-25.43% Pretax Margin-24.73% Return on Equity-74.15% Return on Assets-15.09% Debt Debt-to-Equity Ratio0.62 Current Ratio3.85 Quick Ratio3.82 Sales & Book Value Annual Sales$178.03 million Price / Sales0.41 Cash FlowN/A Price / Cash FlowN/A Book Value$0.17 per share Price / Book1.69Miscellaneous Outstanding Shares257,232,000Free Float224,051,000Market Cap$73.83 million OptionableOptionable Beta2.86 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:ADAP) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptimmune Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptimmune Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.